series-c-plus
Stage
1
Investors
About
MeMed Diagnostics Ltd develops rapid diagnostic assays and platforms that use host immune response signatures and machine learning to accurately distinguish between bacterial and viral infections within 15 minutes, aiding clinical decision-making and antimicrobial stewardship.
Explore MeMed Diagnostics Ltd's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.